Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

    Categories: Antineoplastic and Immunomodulating Agents
  3. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    It blocks some of the enzymes that keep cancer cells from dying. … Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies,

    Categories: Antineoplastic and Immunomodulating Agents
  4. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741] … [L42325] Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents
  5. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

    Categories: Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  6. Target

    Aurora kinase A

    go.drugbank.com/bio_entities/BE0000991
    TargetHumans

    Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase (PubMed:27335426). … Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome

    Synonyms: Ipl1- and aurora-related kinase 1
  7. Drug

    Benzphetamine

    go.drugbank.com/drugs/DB00865
    ApprovedIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

  8. Drug

    Melaleuca alternifolia leaf

    go.drugbank.com/drugs/DB14372
    Investigational

    It is not an approved drug.

    Mixtures: Pimplepatch By Glam Up, SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampoo
  9. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. … [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.

    Categories: Milnacipran and enantiomer, Serotonin and Noradrenaline Reuptake Inhibitors
  10. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    and Community Acquired Pneumonia, among others. … It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.